IDEAYA Biosciences (NASDAQ:IDYA) and Hengrui Pharma presented positive Phase 1 data for IDE849, a potential first-in-class DLL3 TOP1 ADC for Small Cell Lung Cancer (SCLC) at WCLC 2025. The study showed impressive efficacy with a 77.1% overall response rate (ORR) in second-line SCLC patients and 73.2% ORR across all treatment lines at expansion doses.
Key highlights include a 6.7-month median progression-free survival across all lines, with median PFS not yet reached in second-line patients. The drug demonstrated particular efficacy in patients with brain metastases, achieving an 83.3% confirmed ORR at the 2.4 mg/kg dose. The safety profile was manageable, with a low 2% treatment-related discontinuation rate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.